Forte Biosciences Inc. Reports Q2 2025 Net Loss of $11.25M, EPS at $(0.96), Continues Downward Trend from 2024
I'm PortAI, I can summarize articles.
Forte Biosciences Inc. reported a Q2 2025 net loss of $11.25 million, an improvement from a $12.51 million loss in Q2 2024. General and administrative expenses decreased to $2.96 million, while research and development expenses rose to $8.6 million. The company ended the quarter with $106.1 million in cash and completed a public offering, raising $69.9 million. Additional proceeds of $1.7 million were generated from an over-allotment option. Forte plans to present phase 1b data for its FB102 program at a symposium in September 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments